Literature DB >> 33627670

Cannabis use and cannabis use disorder.

Jason P Connor1,2, Daniel Stjepanović3, Bernard Le Foll4,5, Eva Hoch6,7, Alan J Budney8, Wayne D Hall3,9.   

Abstract

Cannabis use disorder (CUD) is an underappreciated risk of using cannabis that affects ~10% of the 193 million cannabis users worldwide. The individual and public health burdens are less than those of other forms of drug use, but CUD accounts for a substantial proportion of persons seeking treatment for drug use disorders owing to the high global prevalence of cannabis use. Cognitive behavioural therapy, motivational enhancement therapy and contingency management can substantially reduce cannabis use and cannabis-related problems, but enduring abstinence is not a common outcome. No pharmacotherapies have been approved for cannabis use or CUD, although a number of drug classes (such as cannabinoid agonists) have shown promise and require more rigorous evaluation. Treatment of cannabis use and CUD is often complicated by comorbid mental health and other substance use disorders. The legalization of non-medical cannabis use in some high-income countries may increase the prevalence of CUD by making more potent cannabis products more readily available at a lower price. States that legalize medical and non-medical cannabis use should inform users about the risks of CUD and provide information on how to obtain assistance if they develop cannabis-related mental and/or physical health problems.

Entities:  

Year:  2021        PMID: 33627670     DOI: 10.1038/s41572-021-00247-4

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  249 in total

1.  Effects of the National Youth Anti-Drug Media Campaign on youths.

Authors:  Robert Hornik; Lela Jacobsohn; Robert Orwin; Andrea Piesse; Graham Kalton
Journal:  Am J Public Health       Date:  2008-10-15       Impact factor: 9.308

2.  Cannabis use and suicide attempts among 86,254 adolescents aged 12-15 years from 21 low- and middle-income countries.

Authors:  Andre F Carvalho; Brendon Stubbs; Davy Vancampfort; Stefan Kloiber; Michael Maes; Joseph Firth; Paul A Kurdyak; Dan J Stein; Jürgen Rehm; Ai Koyanagi
Journal:  Eur Psychiatry       Date:  2018-11-15       Impact factor: 5.361

Review 3.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

4.  The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis.

Authors:  Emily E Tanner-Smith; Sandra Jo Wilson; Mark W Lipsey
Journal:  J Subst Abuse Treat       Date:  2012-07-02

Review 5.  An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use.

Authors:  Alan J Budney; Michael J Sofis; Jacob T Borodovsky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

Review 6.  Contingency Management: Using Incentives to Improve Outcomes for Adolescent Substance Use Disorders.

Authors:  Catherine Stanger; Alan J Budney
Journal:  Pediatr Clin North Am       Date:  2019-12       Impact factor: 3.278

Review 7.  Pharmacotherapy for cannabis dependence: how close are we?

Authors:  Ryan Vandrey; Margaret Haney
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Global statistics on alcohol, tobacco and illicit drug use: 2017 status report.

Authors:  Amy Peacock; Janni Leung; Sarah Larney; Samantha Colledge; Matthew Hickman; Jürgen Rehm; Gary A Giovino; Robert West; Wayne Hall; Paul Griffiths; Robert Ali; Linda Gowing; John Marsden; Alize J Ferrari; Jason Grebely; Michael Farrell; Louisa Degenhardt
Journal:  Addiction       Date:  2018-06-04       Impact factor: 6.526

Review 9.  Current advances in the treatment of adolescent drug use.

Authors:  Ken C Winters; Emily E Tanner-Smith; Elena Bresani; Kathleen Meyers
Journal:  Adolesc Health Med Ther       Date:  2014-11-20

Review 10.  Cannabis Addiction and the Brain: a Review.

Authors:  Amna Zehra; Jamie Burns; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-19       Impact factor: 4.147

View more
  17 in total

1.  Preliminary Eye-Tracking Data as a Nonintrusive Marker for Blood Δ-9-Tetrahydrocannabinol Concentration and Drugged Driving.

Authors:  Ali Shahidi Zandi; Felix J E Comeau; Robert E Mann; Patricia Di Ciano; Eliyas P Arslan; Thomas Murphy; Bernard Le Foll; Christine M Wickens
Journal:  Cannabis Cannabinoid Res       Date:  2021-08-24

2.  Cannabis use disorder treatment use and perceived treatment need in the United States: Time trends and age differences between 2002 and 2019.

Authors:  Melanie S Askari; Katherine M Keyes; Pia M Mauro
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

3.  Induction of dopaminergic neurons for neuronal subtype-specific modeling of psychiatric disease risk.

Authors:  Samuel K Powell; Callan O'Shea; Kayla Townsley; Iya Prytkova; Kristina Dobrindt; Rahat Elahi; Marina Iskhakova; Tova Lambert; Aditi Valada; Will Liao; Seok-Man Ho; Paul A Slesinger; Laura M Huckins; Schahram Akbarian; Kristen J Brennand
Journal:  Mol Psychiatry       Date:  2021-09-07       Impact factor: 13.437

4.  Cannabis Use Disorder: A Behavioral Economic Perspective.

Authors:  Elizabeth R Aston; Benjamin L Berey
Journal:  Curr Addict Rep       Date:  2022-01-07

Review 5.  Clinical management of cannabis withdrawal.

Authors:  Jason P Connor; Daniel Stjepanović; Alan J Budney; Bernard Le Foll; Wayne D Hall
Journal:  Addiction       Date:  2022-01-10       Impact factor: 7.256

6.  Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates.

Authors:  Jakob Manthey; Tom P Freeman; Carolin Kilian; Hugo López-Pelayo; Jürgen Rehm
Journal:  Lancet Reg Health Eur       Date:  2021-09-24

Review 7.  The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.

Authors:  Mashal Ahmed; Isabelle Boileau; Bernard Le Foll; Andre F Carvalho; Stefan Kloiber
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

8.  Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample.

Authors:  Dafna Sara Rubin-Kahana; Ahmed Nabeel Hassan; Marcos Sanches; Bernard Le Foll
Journal:  Front Psychiatry       Date:  2022-04-01       Impact factor: 5.435

Review 9.  Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway.

Authors:  Masaru Tanaka; Fanni Tóth; Helga Polyák; Ágnes Szabó; Yvette Mándi; László Vécsei
Journal:  Biomedicines       Date:  2021-06-25

10.  The Prevalence and Negative Impacts of Substance Use Disorders among People with HIV in the United States: A Real-Time Delphi Survey of Key Stakeholders.

Authors:  Bryan R Garner; Heather J Gotham; Hannah K Knudsen; Brittany A Zulkiewicz; Stephen J Tueller; Marcus Berzofsky; Tom Donohoe; Erika G Martin; L Lauren Brown; Theodore Gordon
Journal:  AIDS Behav       Date:  2021-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.